CDMA, Globalstar versus Iridium, Inmarsat, etc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : CDMA, Globalstar versus Iridium, Inmarsat, etc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Maurice Winn who wrote ()	12/17/1997 3:13:00 PM
From: Maurice Winn	of 381

Rituxan now available for Non-Hodgkin's Lymphoma. 16 December 1997 Genentech and IDEC Pharmaceuticals Corporation announced that RITUXAN [Rituximab] is being shipped today to the oncology medical community. Rituxan was cleared for marketing by the US Food and Drug Administration on 26 November 1997. IDEC invented Rituxan and developed the product in collaboration with Genentech, F Hoffmann-La Roche Ltd of Switzerland and Zenyaku Kogyo Co Ltd. of Japan. IDEC and Genentech will promote Rituxan in the United States and have shared responsibility for product manufacture. Roche will market the product under the tradename MabThera in the rest of world, excluding Japan. Genentech Inc. discovers, develops, manufactures and markets human pharmaceuticals. Eleven of the currently marketed biotechnology products stem from Genentech science. Genentech markets eight biotechnology products in the United States. IDEC Pharmaceuticals focuses on developing targeted immunotherapies for the treatment of cancer and autoimmune disease which are primarily designed to act through immune mechanisms. Genentech Inc. Marie Kennedy 650 225-8751 Media Susan Bentley 650 225-1034 Investors gene.com IDEC Connie Matsui 619 550-8656 It seems that Rituxan is good for low grade NHLs, B-cell, CD20 antigen expressing follicular and other types, but not so hot for intermediate and high grade NHLs. Though still somewhat effective. Why isn't it effective on intermediate B-cells, large and diffuse if they are have CD20? Beats me.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next